- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07939802
A Study to Learn About the Effects of Felzartamab on Daily Living Activities and Its Safety in Adults With Generalized Myasthenia Gravis (gMG) Ages 18 to 80 Years Old (MYAMERGE)
A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Felzartamab Compared to Placebo in Adults With Generalized Myasthenia Gravis
In this study, researchers will learn more about the effects of felzartamab, also known as BIIB148, in adult participants with generalized myasthenia gravis, also known as gMG. This is a type of autoimmune disease that affects the signals sent between nerve cells and the muscles. An autoimmune disease means the body's immune system attacks its own healthy cells.
In people with gMG, the body's immune system makes abnormal antibodies that affect the signals that can be sent between the muscle and the nerves at the neuromuscular junction. The neuromuscular junction is where the nerve and muscle connect. The most common antibodies made in gMG are those that target 1 of 2 types of proteins - AchR (acetylcholine receptor) and MuSK (muscle-specific tyrosine kinase).
In this study, researchers wanted to learn more about a study drug called felzartamab. Researchers think felzartamab may lower the amount of antibodies against AChR or MuSK and allow signals between muscles and nerves to be sent normally again.
The main goal of the study is to compare the effects of felzartamab to a placebo on symptoms and daily living activities in adult participants with gMG. A placebo looks like the study drug but does not contain any medicine.
The main question researchers want to answer is:
- Does felzartamab increase the ability to perform daily activities after 26 weeks of treatment in participants with AChR antibodies?
Researchers will also learn more about:
- How many participants have adverse events and serious adverse events during the study? Adverse events are health problems that may or may not be caused by the study drug.
- How the body processes felzartamab
- How felzartamab affects the participants' disease severity
- How many participants' bodies make antibodies against felzartamab after treatment
This study will be done as follows:
-
Participants will join the study after signing an informed consent form, also known as an ICF.
-
Participants will be screened to check if they can join the study. Participants will then be assigned to a study group based on the type of antibodies they have.
- If participants have AChR antibodies, they will be randomly assigned to receive either felzartamab or a placebo. Neither the participants nor the researchers will know if participants are getting the study drug or the placebo.
- If participants have MuSK antibodies, they will receive felzartamab. In this group, the participants, study doctor, and study staff know which drug the participant is taking.
-
Both felzartamab and the placebo will be given as an intravenous (IV) infusion, which involves giving the drug into a vein.
-
During the study, participants will have regular clinic visits and phone calls. At the visits, participants will have blood and urine samples taken and will also have their overall health checked. The participants will also be asked questions about how they are feeling and how their gMG is affecting their daily lives.
-
After their last dose, participants will enter a follow-up safety period for more testing and monitoring of their health.
연구 개요
상세 설명
The primary objective of this study is to evaluate the efficacy of felzartamab in participants with gMG compared with placebo. The secondary objectives of this study are to evaluate the efficacy, safety, pharmacokinetics (PK) of felzartamab and anti-drug antibodies (ADAs) in participants with gMG.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: US Biogen Clinical Trial Center
- 전화번호: 866-633-4636
- 이메일: clinicaltrials@biogen.com
연구 연락처 백업
- 이름: Global Biogen Clinical Trial Center
- 이메일: clinicaltrials@biogen.com
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
- Documented diagnosis of gMG.
- Myasthenia Gravis Foundation of America (MGFA) clinical Classification II to IVa at Screening and Randomization.
- Corticosteroids must be administered orally on a daily or alternate-day schedule; pulse corticosteroid therapy is not permitted. Concomitant treatment with permitted acetylcholinesterase inhibitor (AChEIs) and/or allowed conventional immunosuppressant standard therapy (ISTs) is allowed, provided all therapies meet protocol-defined requirements.
- Participants receiving AChEIs must have been on a stable dose prior to Randomization.
- Participants receiving Azathioprine must be on treatment and a stable dose prior to Randomization.
- Participants receiving other conventional immunosuppressive drugs (e.g., mycophenolate mofetil, mycophenolic acid, methotrexate, cyclosporine, tacrolimus), or other Sponsor-approved therapy) must be on treatment and on a stable dose prior to Randomization.
- Participants should be up to date on all vaccinations in accordance with local country or regional public health authority guidelines, where feasible. Required vaccinations should be completed at least 4 weeks prior to screening, where applicable. A screening period extension may be permitted to allow completion of required vaccinations.
Key Exclusion Criteria:
- MGFA Class I or IVb, or V at Screening.
- History of myasthenic crisis requiring hospitalization, mechanical ventilation, or intensive care unit admission prior to Screening.
- Anticipated need for rescue therapy between Screening and Randomization.
- Congenital myasthenic syndrome, Lambert-Eaton myasthenic syndrome, or any other neuromuscular disorder that could confound the evaluation of gMG.
- Thymectomy for benign thymoma within 12 months prior to Randomization or planned thymectomy during the study.
- Unresected, active or recurrent thymoma.
- History of malignancy within 5 years prior to Screening except for adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer, or other malignancies considered cured with minimal risk of recurrence, as determined by the Investigator.
NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Cohort 1: Felzartamab or Placebo
Participants will receive multiple intravenous (IV) doses of felzartamab or placebo. |
Administered IV Administered IV
다른 이름들:
|
|
실험적: Cohort 2: Felzartamab
Participants will receive multiple IV doses of felzartamab. |
Administered IV
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Cohort 1: Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 26
기간: Baseline, Week 26
|
Baseline, Week 26
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Cohort 1: Change From Baseline in Quantitative Myasthenia Gravis (QMG) Total Score at Week 26
기간: Baseline, Week 26
|
Baseline, Week 26
|
|
Cohorts 1 and 2: Number of Participants With Adverse Events (AEs) and Adverse Events of Special Interest (AESI)
기간: From first dose of study drug up to end of study follow-up (Up to Week 52)
|
From first dose of study drug up to end of study follow-up (Up to Week 52)
|
|
Cohorts 1 and 2: Felzartamab Serum Concentrations Over Time
기간: Predose and at multiple timepoints postdose up to Week 44
|
Predose and at multiple timepoints postdose up to Week 44
|
|
Cohorts 1and 2: Number of Participants with Anti-drug Antibodies (ADAs) Against Felzartamab
기간: Baseline up to Week 52
|
Baseline up to Week 52
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Medical Director, Biogen
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 299MG201
- 2026-527803-94 (기타 식별자: EU CT Number)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .